Jose L. Rivas
About
Jose L. Rivas is a scholar working on Rheumatology, Hematology and Genetics.
According to data from OpenAlex, Jose L. Rivas has authored 27 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Rheumatology, 9 papers in Hematology and 8 papers in Genetics. Recurrent topics in Jose L. Rivas's work include Rheumatoid Arthritis Research and Therapies (20 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Jose L. Rivas is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (20 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Jose L. Rivas collaborates with scholars based in Spain, United States and France. Jose L. Rivas's co-authors include Cunshan Wang, Carol A. Connell, Sujatha Menon, Steven R. Ytterberg, Deepak L. Bhatt, Gary G. Koch, Andrea Shapiro, Keith S. Kanik, Ted R. Mikuls and R. Fleischmann and has published in prestigious journals such as New England Journal of Medicine, Circulation and Diabetologia.
In The Last Decade
Jose L. Rivas
23 papers receiving 1.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jose L. Rivas Spain | 11 | 852 | 308 | 306 | 240 | 233 | 27 | 1.4k | ||
| Rebecca Germino United States | 9 | 631 0.7× | 234 0.8× | 338 1.1× | 214 0.9× | 168 0.7× | 22 | 1.2k | ||
| Hubert van Hoogstraten United States | 18 | 917 1.1× | 516 1.7× | 429 1.4× | 122 0.5× | 170 0.7× | 60 | 1.4k | ||
| Jacques‐Eric Gottenberg France | 20 | 961 1.1× | 324 1.1× | 328 1.1× | 121 0.5× | 254 1.1× | 58 | 1.5k | ||
| Wenhui Xie China | 22 | 533 0.6× | 127 0.4× | 317 1.0× | 133 0.6× | 233 1.0× | 93 | 1.4k | ||
| Sergio Schwartzman United States | 21 | 955 1.1× | 398 1.3× | 548 1.8× | 78 0.3× | 98 0.4× | 59 | 1.4k | ||
| M J Cuadrado United Kingdom | 13 | 814 1.0× | 176 0.6× | 403 1.3× | 169 0.7× | 71 0.3× | 21 | 1.4k | ||
| Šárka Forejtová Czechia | 15 | 1.0k 1.2× | 403 1.3× | 401 1.3× | 92 0.4× | 213 0.9× | 32 | 1.4k | ||
| Marcel D. Posthumus Netherlands | 20 | 671 0.8× | 215 0.7× | 347 1.1× | 160 0.7× | 149 0.6× | 30 | 1.4k | ||
| Jiuliang Zhao China | 24 | 1.2k 1.4× | 234 0.8× | 570 1.9× | 102 0.4× | 113 0.5× | 231 | 2.3k | ||
| Mercedes Alperí Spain | 25 | 744 0.9× | 247 0.8× | 595 1.9× | 79 0.3× | 183 0.8× | 91 | 1.3k |
Countries citing papers authored by Jose L. Rivas
Since
Specialization
Citations
This map shows the geographic impact of Jose L. Rivas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jose L. Rivas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jose L. Rivas more than expected).
Fields of papers citing papers by Jose L. Rivas
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jose L. Rivas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jose L. Rivas. The network helps show where Jose L. Rivas may publish in the future.
Co-authorship network of co-authors of Jose L. Rivas
This figure shows the co-authorship network connecting the top 25 collaborators of Jose L. Rivas. A scholar is included among the top collaborators of Jose L. Rivas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jose L. Rivas. Jose L. Rivas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Giles, Jon T., Christina Charles‐Schoeman, Maya H Buch, et al.. (2025). Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. Annals of the Rheumatic Diseases. 85(1). 103–113.
2.
Citera, Gustavo, Eduardo Mysler, Adriana María Kakehasi, et al.. (2024). Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors. JCR Journal of Clinical Rheumatology. 30(5). 208–216.
3.
Pope, Janet, Axel Finckh, Lucía Silva-Fernández, et al.. (2024). Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention. Open Access Rheumatology Research and Reviews. Volume 16. 115–126.
4.
Batko, Bogdan, et al.. (2024). Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance. Rheumatology and Therapy. 11(5). 1217–1235.
5.
Kristensen, Lars Erik, Silvio Danese, Cunshan Wang, et al.. (2023). Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Annals of the Rheumatic Diseases. 82(7). 901–910.
6.
Charles‐Schoeman, Christina, Maya H Buch, Deepak L. Bhatt, et al.. (2022). POS0674 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE. Annals of the Rheumatic Diseases. 81. 611–612.
7.
Charles‐Schoeman, Christina, Maya H Buch, Maxime Dougados, et al.. (2022). Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Annals of the Rheumatic Diseases. 82(1). 119–129.
8.
Xiang, Kun, David D. McManus, Jose L. Rivas, et al.. (2021). Abstract 6905: Implementing, Launching and Sustaining a Quality Improvement Initiative in the Era of COVID-19: Challenges and Successes. Circulation. 144(Suppl_1).
9.
Kremer, Joel M., Clifton O. Bingham, Laura C. Cappelli, et al.. (2021). Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry. ACR Open Rheumatology. 3(3). 173–184.
10.
Winthrop, Kevin, Jeffrey R. Curtis, Kunihiro Yamaoka, et al.. (2021). Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatology and Therapy. 9(1). 243–263.
11.
Cohen, Stanley, Naonobu Sugiyama, Jose L. Rivas, et al.. (2021). POS0651 CLINICAL AND FUNCTIONAL RESPONSE TO TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: PROBABILITY PLOT ANALYSIS OF RESULTS FROM A 48-WEEK PHASE 3b/4 METHOTREXATE WITHDRAWAL STUDY. Annals of the Rheumatic Diseases. 80. 564–565.
12.
Cohen, Stanley, Janet Pope, Boulos Haraoui, et al.. (2019). Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. The Lancet Rheumatology. 1(1). e23–e34.
13.
Taylor, Peter C., Mart van de Laar, Jeffrey R. Curtis, et al.. (2019). AB0449 PAIN REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB MONOTHERAPY WITH OR WITHOUT PAIN MEDICATION: A POST HOC ANALYSIS OF POOLED DATA FROM PHASE 2, PHASE 3 AND PHASE 3B/4 STUDIES. Annals of the Rheumatic Diseases. 78. 1687–1688.
14.
Dikranian, Ara, Valderílio Feijó Azevedo, Louis Bessette, et al.. (2018). FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY. JCR Journal of Clinical Rheumatology. 25.
15.
Rivas, Jose L., et al.. (2018). Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Frontiers in Immunology. 9. 1028–1028.
16.
Miguel, Eugenio de, Alfonso Corrales, Manuel Romero‐Gómez, et al.. (2017). A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis. Rheumatology International. 37(8). 1347–1356.
17.
Gaynor, Jeffrey J., Gaetano Ciancio, Giselle Guerra, et al.. (2015). Multivariable risk of developing new onset diabetes after transplant—results from a single‐center study of 481 adult, primary kidney transplant recipients. Clinical Transplantation. 29(4). 301–310.
18.
Gaynor, Jeffrey J., Gaetano Ciancio, Giselle Guerra, et al.. (2014). Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant. Diabetologia. 58(2). 334–345.
19.
Rivas, Jose L., Charles H Rowell, & Ana Martı́nez. (2003). An Interview with Jose Luis Rivas. Callaloo. 26(4). 975–977.
20.
Blasco, E., et al.. (1990). Immunohistological patterns of blood group ABO and type 1 chain (Lewis a Lewis b) and type 2 chain (H‐2, Y) antigens in normal uterine cervix. Tissue Antigens. 36(1). 8–11.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rebecca Germino Breakdown of academic impact, for papers by Hubert van Hoogstraten Breakdown of academic impact, for papers by Jacques‐Eric Gottenberg Breakdown of academic impact, for papers by Wenhui Xie Breakdown of academic impact, for papers by Sergio Schwartzman Breakdown of academic impact, for papers by M J Cuadrado Breakdown of academic impact, for papers by Šárka Forejtová Breakdown of academic impact, for papers by Marcel D. Posthumus Breakdown of academic impact, for papers by Jiuliang Zhao Breakdown of academic impact, for papers by Mercedes Alperí